Skip to main content
syn
Daily Digest
Business

Google-backed Isomorphic raises $2.1 billion for AI drug discovery

Published Tuesday, May 12, 2026 · Updated May 13

Share on X

Source Balance

Limited Data
Left 0%Center 100%Right 0%

Coverage is limited to a single source, lacking diverse perspectives.

Media Analysis

AI synthesis

Isomorphic Labs, an AI-driven drug discovery company backed by Google, has successfully raised $2.1 billion in its latest funding round. The funding, led by Thrive Capital with contributions from Google Ventures and Alphabet, is intended to scale its drug design engine, advance its mission to combat diseases, and support the goal of initiating clinical trials by late 2026.

What We Know — Key Points

  • Isomorphic Labs raised $2.1 billion in its latest funding round, led by Thrive Capital with participation from Google Ventures and Alphabet.
  • The capital injection aims to scale Isomorphic Labs' drug design engine, accelerate its mission to solve diseases, and expects clinical trials by late 2026.

What Is Claimed — Perspectives

  • Channel News AsiaCenter

    Isomorphic Labs, an AI-driven drug discovery company, secured $2.1 billion in funding led by Thrive Capital, with participation from Google Ventures and Alphabet. This capital injection aims to scale its drug design engine and accelerate its mission to solve diseases, with clinical trials expected by late 2026.

AI-Generated Content

  • This topic was generated by an AI system.
  • Key points, perspectives, bias labels, and categorisation may contain errors.
  • This is not journalism. Do not rely on this content for critical decisions.
  • Read our full AI disclaimer for details.